Comparison of onset time, duration of action, and intubating conditions after cisatracurium 0.15 mg/kg in young and elderly patients

Matias Vested, Camilla Meno Kristensen, Pernille Pape, Malene Vang, Mian Hartoft, Caroline Hjelmdal, Lars Simon Rasmussen, Matias Vested, Camilla Meno Kristensen, Pernille Pape, Malene Vang, Mian Hartoft, Caroline Hjelmdal, Lars Simon Rasmussen

Abstract

Introduction: Tracheal intubation during anesthesia can be facilitated by the neuromuscular blocking agent cisatracurium. However, limited data exists about onset time, duration of action and effect on intubating conditions in elderly patients above 80 years of age. We hypothesized that elderly patients would present a longer onset time and duration of action compared to younger adults.

Methods: This prospective observational study included 31 young (18-40 years) and 29 elderly (≥ 80 years) patients. Patients were given fentanyl 2 μg/kg and propofol 1.5-2.5 mg/kg for induction of anesthesia and maintained with remifentanil and propofol. Monitoring of neuromuscular function was performed with acceleromyography. Primary outcome was onset time defined as time from injection of cisatracurium 0.15 mg/kg (based on ideal body weight) to a train-of-four (TOF) count of 0. Other outcomes included duration of action (time to TOF ratio ≥ 0.9), intubation conditions using the Fuchs-Buder scale and the Intubating Difficulty Scale (IDS), and occurrence of hoarseness and sore throat postoperatively.

Results: Elderly patients had significantly longer onset time compared with younger patients; 297 seconds (SD 120) vs. 199 seconds (SD 59) (difference: 98 seconds (95% CI: 49-147), P < 0.001)). Duration of action was also significantly longer in elderly patients compared with younger patients; 89 minutes (SD 17) vs. 77 minutes (SD 14) (difference: 12 minutes (95% CI: 2.5-20.5) P = 0.01)). No difference was found in the proportion of excellent intubating conditions (Fuchs-Buder); 19/29 (66%) vs 21/31 (68%) (P = 0.86) or IDS score (P = 0.74). A larger proportion of elderly patients reported hoarseness 24 hours postoperatively; 62% vs 34% P = 0.04.

Conclusion: In elderly patients cisatracurium 0.15 mg/kg had significantly longer onset time and duration of action compared with younger patients. No difference was found in intubating conditions at a TOF count of 0.

Trial registration: Clinicaltrials.gov (NCT04921735, date of registration 10 June 2021).

Keywords: Duration of action; Elderly patients; Intubating conditions; Neuromuscular blocking agents; Onset time.

Conflict of interest statement

MVE has received speaker’s fees from the pharmaceutical company MSD.

CMK, PP, MV, MH, CH and LSR declare no conflicts of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart

References

    1. Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear TD, Vender JS, et al. Residual neuromuscular block in the elderly: incidence and clinical implications. Anesthesiology. 2015;123:1322–1326. doi: 10.1097/ALN.0000000000000865.
    1. Doenicke A, Soukup J, Hoernecke R, Moss J. The lack of histamine release with cisatracurium: a double-blind comparison with vecuronium. Anesth Analg. 1997;84:623–628.
    1. Ornstein E, Lien CA, Matteo RS, Ostapkovich ND, Diaz J, Wolf KB. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Anesthesiology. 1996;84:520–525. doi: 10.1097/00000542-199603000-00005.
    1. Manku K, Bacchetti P, Leung JM. Prognostic significance of postoperative in-hospital complications in elderly patients. I Long-term survival Anesth Analg. 2003;96:583–589.
    1. Xiaobo F, Jianjuan K, Yanlin W. Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. Brazilian J Med Biol Res. 2012;45:676–680. doi: 10.1590/S0100-879X2012007500076.
    1. Mellinghoff H, Radbruch L, Diefenbach C, Buzello W. A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion. Anesth Analg. 1996;83:1072–1075. doi: 10.1213/00000539-199611000-00030.
    1. Vestal RE. Aging and pharmacology. Cancer. 1997;80:1302–1310. doi: 10.1002/(SICI)1097-0142(19971001)80:7<1302::AID-CNCR16>;2-B.
    1. Bjerring C, Vested M, Arleth T, Eriksen K, Albrechtsen C, Rasmussen LS. Onset time and duration of action of rocuronium 0.6 mg/kg in patients above 80 years of age: a comparison with young adults. Acta Anaesthesiol Scand. 2020;64:1082–1088. doi: 10.1111/aas.13645.
    1. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111:120–128. doi: 10.1213/ANE.0b013e3181da832d.
    1. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg. 2010;111:129–140. doi: 10.1213/ANE.0b013e3181da8312.
    1. Kirmeier E, Eriksson LI, Lewald H, Fagerlund MJ, Hoeft A, Hollmann M, Meistelman C, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019;7:129–140. doi: 10.1016/S2213-2600(18)30294-7.
    1. Arain SR, Kern S, Ficke DJ, Ebert TJ. Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta Anaesthesiol Scand. 2005;49:312–315. doi: 10.1111/j.1399-6576.2005.00634.x.
    1. Sun R, Tian JH, Li L, Tian HL, Jia WQ, Yang KH, et al. Effect of ephedrine on intubating conditions created by propofol and rocuronium: a meta-analysis. J Evid Based Med. 2012;5:209–215. doi: 10.1111/jebm.12003.
    1. Adnet F, Borron SW, Racine SX, Clemessy JL, Fournier JL, Plaisance P. The intubation difficulty scale (IDS): proposal and evaluation of a new score characterizing the complexity of endotracheal intubation. Anesthesiology. 1997;87:1290–1297. doi: 10.1097/00000542-199712000-00005.
    1. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789–808. doi: 10.1111/j.1399-6576.2007.01352.x.
    1. Carroll MT, Mirakhur RK, Lowry D, Glover P, Kerr CJ. A comparison of the neuromuscular blocking effects and reversibility of cisatracurium and atracurium. Anaesthesia. 1998;53:744–748. doi: 10.1046/j.1365-2044.1998.00530.x.
    1. Doenicke AW, Czeslick E, Moss J, Hoernecke R. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration. Anesth Analg. 1998;87:434–438. doi: 10.1213/00000539-199808000-00038.
    1. Kleine-Brueggeney M, Buttenberg M, Greif R, Nabecker S, Theiler L. Evaluation of three unchannelled videolaryngoscopes and the Macintosh laryngoscope in patients with a simulated difficult airway: a randomised, controlled trial. Anaesthesia. 2017;72:370–378. doi: 10.1111/anae.13714.
    1. Sorooshian SS, Stafford MA, Eastwood NB, Boyd AH, Hull CJ, Wright PM. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. Anesthesiology. 1996;84:1083–1091. doi: 10.1097/00000542-199605000-00010.
    1. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346–354. doi: 10.1161/01.CIR.0000048893.62841.F7.
    1. Vested M, Sørensen AM, Bjerring C, Christensen RE, Dinesen F, Vang M. A blinded randomised study comparing intubating conditions after either rocuronium 0.6 mg kg −1 or remifentanil 2 μg kg −1 in elderly patients. Acta Anaesthesiol Scand. 2021;65:1367–1373. doi: 10.1111/aas.13957.
    1. Takagi S, Sugaya N, Kiuchi N, Iwasa A, Itagaki M, Seki A, et al. High-dose rocuronium-induced paralysis of the adductor pollicis muscle facilitates detection of the timing for tracheal intubation in elderly patients: a randomized double-blind study. J Anesth. 2020;34:876–880. doi: 10.1007/s00540-020-02831-6.
    1. Meistelman C, Plaud B, Donati F. Rocuronium (ORG 9426) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans. Can J Anaesth. 1992;39:665–669. doi: 10.1007/BF03008227.
    1. Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109:188–197. doi: 10.1097/ALN.0b013e31817f5bc7.
    1. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology. 2008;109:389–398. doi: 10.1097/ALN.0b013e318182af3b.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する